GC Pharma Hones R&D Focus, Tweaks US Immunoglobulin Strategy
Leading South Korean pharma firm GC Pharma realigns R&D priorities and resources and changes US strategy amid delayed approval of its immunoglobulin product.
You may also be interested in...
The South Korean pharma firm, which has been focusing on North America, decides to sell two subsidiaries there as the prolonged coronavirus pandemic further delays commercial manufacturing of plasma products.
Green Cross has hit a bump in its journey to commercialize an immunoglobulin product in the US, but analysts say the approval delay will not be a significant obstacle to its longer term North American strategy.
Green Cross has overhauled the global development strategy for its hemophilia A therapy GreenGene F, halting slow-progressing Phase III trials in the US and Europe and shifting its focus instead to the fast-growing China market.